Terakura Seitaro, Azuma Eiichi, Murata Makoto, Kumamoto Tadashi, Hirayama Masahiro, Atsuta Yoshiko, Kodera Yoshihisa, Yazaki Makoto, Naoe Tomoki, Kato Koji
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokai Cord Blood Bank, Nagoya, Japan.
Biol Blood Marrow Transplant. 2007 Jul;13(7):822-30. doi: 10.1016/j.bbmt.2007.03.006. Epub 2007 Apr 30.
Umbilical cord blood (UCB) transplantation is limited by the low number of hematopoietic stem cells in UCB units, which results in a low engraftment rate in transplant recipients. Here, we measured the total nucleated cell count and CD34(+), CD3(+), CD4(+), CD8(+), CD14(+), and CD16(+)/56(+) cell doses in each UCB unit and evaluated their influence on engraftment and other outcomes in 146 recipients. Multivariate analysis showed a significant association between a higher incidence of successful engraftment and a dose of CD34(+) and CD8(+) cells above the median (1.4 x 10(5) and 15.7 x 10(5) cells/kg, respectively). Engraftment occurred 4 days earlier in patients who received UCB with more than the median dose of CD34(+) cells than those receiving UCB at or below the median. Stratification of the group according to CD34(+) cell dose revealed a significant influence of the CD8(+) cell dose on the time to achieve neutrophil engraftment in patients receiving a lower CD34(+) cell dose, whereas there was no significant influence in the patients receiving a higher CD34(+) cell dose. These results suggest that consideration of CD34(+) and CD8(+) cell doses in UCB units may improve the engraftment in recipients of UCB transplantation.
脐带血(UCB)移植受到UCB单位中造血干细胞数量少的限制,这导致移植受者的植入率较低。在此,我们测量了每个UCB单位中的总核细胞计数以及CD34(+)、CD3(+)、CD4(+)、CD8(+)、CD14(+)和CD16(+)/56(+)细胞剂量,并评估了它们对146名受者植入及其他结局的影响。多变量分析显示,成功植入的较高发生率与高于中位数的CD34(+)和CD8(+)细胞剂量(分别为1.4×10⁵和15.7×10⁵细胞/千克)之间存在显著关联。接受CD34(+)细胞剂量高于中位数的UCB的患者,其植入时间比接受中位数或低于中位数剂量UCB的患者早4天。根据CD34(+)细胞剂量对该组进行分层显示,CD8(+)细胞剂量对接受较低CD34(+)细胞剂量的患者实现中性粒细胞植入的时间有显著影响,而对接受较高CD34(+)细胞剂量的患者则无显著影响。这些结果表明,考虑UCB单位中的CD34(+)和CD8(+)细胞剂量可能会改善UCB移植受者的植入情况。